These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

286 related articles for article (PubMed ID: 37450324)

  • 21. Supramolecular Cyclic Dinucleotide Nanoparticles for STING-Mediated Cancer Immunotherapy.
    Xu L; Deng H; Wu L; Wang D; Shi L; Qian Q; Huang X; Zhu L; Gao X; Yang J; Su Y; Feng J; Zhu X
    ACS Nano; 2023 Jun; 17(11):10090-10103. PubMed ID: 37253192
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Discovery of IACS-8803 and IACS-8779, potent agonists of stimulator of interferon genes (STING) with robust systemic antitumor efficacy.
    Ager CR; Zhang H; Wei Z; Jones P; Curran MA; Di Francesco ME
    Bioorg Med Chem Lett; 2019 Oct; 29(20):126640. PubMed ID: 31500996
    [TBL] [Abstract][Full Text] [Related]  

  • 23. TLR9 and STING agonists synergistically induce innate and adaptive type-II IFN.
    Temizoz B; Kuroda E; Ohata K; Jounai N; Ozasa K; Kobiyama K; Aoshi T; Ishii KJ
    Eur J Immunol; 2015 Apr; 45(4):1159-69. PubMed ID: 25529558
    [TBL] [Abstract][Full Text] [Related]  

  • 24. DMXAA causes tumor site-specific vascular disruption in murine non-small cell lung cancer, and like the endogenous non-canonical cyclic dinucleotide STING agonist, 2'3'-cGAMP, induces M2 macrophage repolarization.
    Downey CM; Aghaei M; Schwendener RA; Jirik FR
    PLoS One; 2014; 9(6):e99988. PubMed ID: 24940883
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A STING Agonist Given with OX40 Receptor and PD-L1 Modulators Primes Immunity and Reduces Tumor Growth in Tolerized Mice.
    Foote JB; Kok M; Leatherman JM; Armstrong TD; Marcinkowski BC; Ojalvo LS; Kanne DB; Jaffee EM; Dubensky TW; Emens LA
    Cancer Immunol Res; 2017 Jun; 5(6):468-479. PubMed ID: 28483787
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Polymersome-mediated cytosolic delivery of cyclic dinucleotide STING agonist enhances tumor immunotherapy.
    Zheng H; Guo B; Qiu X; Xia Y; Qu Y; Cheng L; Meng F; Zhong Z
    Bioact Mater; 2022 Oct; 16():1-11. PubMed ID: 35386324
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Structure-Activity relationship study of benzothiophene oxobutanoic acid analogues leading to novel stimulator of interferon gene (STING) agonists.
    Shen A; Li X; Zhang Y; Ma J; Xiao R; Wang X; Song Z; Liu Z; Geng M; Zhang A; Xie Z; Ding C
    Eur J Med Chem; 2022 Nov; 241():114627. PubMed ID: 35963129
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Engineering and Delivery of cGAS-STING Immunomodulators for the Immunotherapy of Cancer and Autoimmune Diseases.
    Zhou S; Cheng F; Zhang Y; Su T; Zhu G
    Acc Chem Res; 2023 Nov; 56(21):2933-2943. PubMed ID: 37802125
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical applications of STING agonists in cancer immunotherapy: current progress and future prospects.
    Wang B; Yu W; Jiang H; Meng X; Tang D; Liu D
    Front Immunol; 2024; 15():1485546. PubMed ID: 39421752
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Design, Synthesis, and Biochemical and Biological Evaluation of Novel 7-Deazapurine Cyclic Dinucleotide Analogues as STING Receptor Agonists.
    Vavřina Z; Perlíková P; Milisavljević N; Chevrier F; Smola M; Smith J; Dejmek M; Havlíček V; Buděšínský M; Liboska R; Vaneková L; Brynda J; Boura E; Řezáčová P; Hocek M; Birkuš G
    J Med Chem; 2022 Oct; 65(20):14082-14103. PubMed ID: 36201304
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prolonged activation of innate immune pathways by a polyvalent STING agonist.
    Li S; Luo M; Wang Z; Feng Q; Wilhelm J; Wang X; Li W; Wang J; Cholka A; Fu YX; Sumer BD; Yu H; Gao J
    Nat Biomed Eng; 2021 May; 5(5):455-466. PubMed ID: 33558734
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Induction of tumor regression by intratumoral STING agonists combined with anti-programmed death-L1 blocking antibody in a preclinical squamous cell carcinoma model.
    Gadkaree SK; Fu J; Sen R; Korrer MJ; Allen C; Kim YJ
    Head Neck; 2017 Jun; 39(6):1086-1094. PubMed ID: 28323387
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A robust microparticle platform for a STING-targeted adjuvant that enhances both humoral and cellular immunity during vaccination.
    Junkins RD; Gallovic MD; Johnson BM; Collier MA; Watkins-Schulz R; Cheng N; David CN; McGee CE; Sempowski GD; Shterev I; McKinnon K; Bachelder EM; Ainslie KM; Ting JP
    J Control Release; 2018 Jan; 270():1-13. PubMed ID: 29170142
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effective delivery of STING agonist using exosomes suppresses tumor growth and enhances antitumor immunity.
    McAndrews KM; Che SPY; LeBleu VS; Kalluri R
    J Biol Chem; 2021; 296():100523. PubMed ID: 33711340
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Antitumor activity of a systemic STING-activating non-nucleotide cGAMP mimetic.
    Chin EN; Yu C; Vartabedian VF; Jia Y; Kumar M; Gamo AM; Vernier W; Ali SH; Kissai M; Lazar DC; Nguyen N; Pereira LE; Benish B; Woods AK; Joseph SB; Chu A; Johnson KA; Sander PN; Martínez-Peña F; Hampton EN; Young TS; Wolan DW; Chatterjee AK; Schultz PG; Petrassi HM; Teijaro JR; Lairson LL
    Science; 2020 Aug; 369(6506):993-999. PubMed ID: 32820126
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Vinylphosphonate-based cyclic dinucleotides enhance STING-mediated cancer immunotherapy.
    Dejmek M; Brazdova A; Otava T; Polidarova MP; Klíma M; Smola M; Vavrina Z; Buděšínský M; Dračínský M; Liboska R; Boura E; Birkuš G; Nencka R
    Eur J Med Chem; 2023 Nov; 259():115685. PubMed ID: 37567057
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Combination of oral STING agonist MSA-2 and anti-TGF-β/PD-L1 bispecific antibody YM101: a novel immune cocktail therapy for non-inflamed tumors.
    Yi M; Niu M; Wu Y; Ge H; Jiao D; Zhu S; Zhang J; Yan Y; Zhou P; Chu Q; Wu K
    J Hematol Oncol; 2022 Oct; 15(1):142. PubMed ID: 36209176
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A critical role of STING-triggered tumor-migrating neutrophils for anti-tumor effect of intratumoral cGAMP treatment.
    Nagata M; Kosaka A; Yajima Y; Yasuda S; Ohara M; Ohara K; Harabuchi S; Hayashi R; Funakoshi H; Ueda J; Kumai T; Nagato T; Oikawa K; Harabuchi Y; Esteban C; Ohkuri T; Kobayashi H
    Cancer Immunol Immunother; 2021 Aug; 70(8):2301-2312. PubMed ID: 33507344
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Control of STING Agonistic/Antagonistic Activity Using Amine-Skeleton-Based c-di-GMP Analogues.
    Yanase Y; Tsuji G; Nakamura M; Shibata N; Demizu Y
    Int J Mol Sci; 2022 Jun; 23(12):. PubMed ID: 35743289
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A novel self-assembled nucleobase-nanofiber platform of CDN to activate the STING pathway for synergistic cancer immunotherapy.
    Dong W; Xu L; Chang C; Jiang T; Chen CP; Zhang G
    Colloids Surf B Biointerfaces; 2023 Dec; 232():113597. PubMed ID: 37862947
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.